CBPO [China Biologic Products] 8-K: FOR RELEASE November 5, 2013 China Biologic Reports

[FOR RELEASE November 5, 2013 China Biologic Reports Financial Results for the Third Quarter and First Nine Months of 2013 --3Q13 Total Sales of $53.2 Million / 9M Total Sales Up 6.6%-- --3Q13 Operating Income Up 13.4% / 9M Operating Income Up 23.0%-- --3Q13 Operating Margin Up 520 bp to 43.6% / 9M Operating Margin Up to 46.3% -- --3Q13] []

CO [Chinard Bloodrp] EFFECT: .FormData {color: blue; background-color: white; font-size: small; font-family:

[.FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif} .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif} .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif} .FormText {font-size: x-small; font-family: arial, helvetica,ns-serif} .SmallFormText {font-size: xx-small; font-family: arial, helvetica,ns-serif} .FormTitle {font-size: medium; font-family: arial, helvetica,ns-serif; font-weight: bold} .FormName {font-size: large; font-family: arial,]

By | 2016-02-04T15:33:58+00:00 November 5th, 2013|Categories: Chinese Stocks, CO, Webplus ver|Tags: , , , , , |0 Comments

CBPO [China Biologic Products] 10-Q:

[] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [David (Xiaoying) Gao , the Chief Executive Officer of CHINA BIOLOGIC PRODUCTS, INC. (the “Company”), DOES HEREBY CERTIFY that: 1. September 30 , 201 3 2. 5 th day of November , 201 3 . David (Xiaoying) Gao Chief Executive Officer A signed original of this written statement required by Section 906 has been provided to China Biologic Products, Inc.] [Ming Yang , the Chief Financial Officer of CHINA BIOLOGIC PRODUCTS, INC. (the “Company”), DOES HEREBY CERTIFY that: 1. 3 2. 5 th day of November , 201 3 . Ming Yang Ming Yang Chief Financial Officer (Principal Financial Officer) A signed original of this written statement required by Section 906 has been provided to China Biologic Products, Inc. and]

OSN [Ossen Innovation] 6-K: Ossen Innovation Announces Two New Steel Strand Supply

[Ossen Innovation Announces Two New Steel Strand Supply Contracts for Bridge and Highway Infrastructure Projects in Anhui Province SHANGHAI, November 5, 2013 -- Ossen Innovation Co., Ltd. ("Ossen" or the "Company") (Nasdaq: OSN), a China-based manufacturer of an array of plain surface, rare earth and zinc coated pre-stressed steel materials, today announced that it has been awarded two contracts to] [FORM 6-K OSSEN INNOVATION CO., LTD. 518 SHANGCHENG ROAD, FLOOR 17, SHANGHAI, 200120, PEOPLE’S REPUBLIC OF CHINA x ¨ Form 20-F ¨ x Yes OSSEN INNOVATION CO., LTD. Description 99.1 Press Release of Ossen Innovation Co., Ltd., dated November 5, 2013 6-K 1 v359194_6k.htm 6-K]

EGT [Entertainment Gaming Asia] 8-K: CONTACTS: Entertainment Gaming Asia Inc. Traci Mangini tracimangini@EGT-Group.com

[CONTACTS: Entertainment Gaming Asia Inc. Traci Mangini tracimangini@EGT-Group.com 312/867-0848 RESULTS ENTERTAINMENT GAMING ASIA INC. REPORTS THIRD QUARTER 2013 AND PROVIDES MARKET UPDATE Hong Kong – November 5, 2013 – Entertainment Gaming Asia Inc. (NASDAQ: EGT) (“Entertainment Gaming Asia” or “the Company”), a leading gaming company focused on emerging gaming markets in Pan-Asia, today reported operating results for the third quarter] [ENTERTAINMENT GAMING ASIA INC. Nevada 001-32161 91-1696010 (State or Other Jurisdiction of Incorporation) (I.R.S. Employer Identification Number) Unit C1, Ground Floor, Koon Wah Building No. 2 Yuen Shun Circuit Yuen Chau Kok, Shatin New Territories, Hong Kong SAR + 852-3147-6600 Not applicable (Former name or former address, if changed since last report) o o o o Item 2.02 Results of]

By | 2016-03-13T23:06:37+00:00 November 5th, 2013|Categories: Chinese Stocks, EGT, Webplus ver|Tags: , , , , , |0 Comments

MR [Mindray Medical International] 6-K: Mindray Announces Up to $200 Million Share Repurchase

[Mindray Announces Up to $200 Million Share Repurchase Program Shenzhen, China – November 4, 2013 – Mindray Medical International Limited (“Mindray” or “Company”, NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, today announced that its Board of Directors has approved a share repurchase program. The program is authorized to be in effect starting from today and]

By | 2016-03-04T04:38:31+00:00 November 4th, 2013|Categories: Chinese Stocks, MR, Webplus ver|Tags: , , , , , |0 Comments

MR [Mindray Medical International] 6-K: Mindray Announces Third Quarter 2013 Financial Results Shenzhen,

[Mindray Announces Third Quarter 2013 Financial Results Shenzhen, China – November 4, 2013 – Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the third quarter ended September 30, 2013. Highlights for Third Quarter 2013 • Net revenues increased 15.3% year-over-year to $296.3 million. International]

By | 2016-03-04T04:35:33+00:00 November 4th, 2013|Categories: Chinese Stocks, MR, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar